Calamos Advisors LLC Invests $2.40 Million in Waters Corporation $WAT

Calamos Advisors LLC purchased a new position in shares of Waters Corporation (NYSE:WAT) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 8,061 shares of the medical instruments supplier’s stock, valued at approximately $2,401,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Zions Bancorporation National Association UT grew its stake in Waters by 121.2% in the 4th quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 40 shares during the period. SHP Wealth Management purchased a new stake in Waters in the 4th quarter worth $32,000. DV Equities LLC acquired a new position in Waters during the fourth quarter worth $32,000. Anchor Investment Management LLC purchased a new position in Waters during the first quarter valued at $27,000. Finally, Louisbourg Investments Inc. purchased a new position in Waters during the first quarter valued at $30,000. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Waters Stock Down 0.3%

Shares of NYSE:WAT opened at $375.25 on Thursday. Waters Corporation has a 52-week low of $275.05 and a 52-week high of $414.15. The stock has a market cap of $36.85 billion, a P/E ratio of 47.68, a PEG ratio of 2.28 and a beta of 1.20. The business has a fifty day moving average of $361.26 and a two-hundred day moving average of $346.44. The company has a quick ratio of 1.13, a current ratio of 1.79 and a debt-to-equity ratio of 0.32.

Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The firm had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the previous year, the company posted $2.25 EPS. The company’s revenue was up 91.4% compared to the same quarter last year. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. On average, research analysts expect that Waters Corporation will post 14.51 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. HSBC lifted their price objective on Waters from $415.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. UBS Group boosted their price target on Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Wells Fargo & Company raised their price objective on Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Piper Sandler assumed coverage on shares of Waters in a report on Thursday, June 11th. They set a “neutral” rating and a $400.00 target price for the company. Finally, The Goldman Sachs Group increased their target price on shares of Waters from $380.00 to $425.00 and gave the company a “buy” rating in a research report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $401.60.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.